Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including…
<!-- Name:DistributionId Value:8830389 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->…
Browsing Tag
atrophy
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection)…
<!-- Name:DistributionId Value:8823381 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Wearable health sensor for monitoring muscle atrophy: New device could allow for…
Researchers at The Ohio State University have fabricated the first wearable sensor designed to detect and monitor muscle atrophy.
A condition involving the loss of skeletal muscle mass and…
FDA Approves First Treatment for Geographic Atrophy
FRIDAY, Feb. 24, 2023 (HealthDay News) -- Pegcetacoplan (SYFOVRE) has been approved by the U.S. Food and Drug Administration as the first and only treatment for geographic atrophy (GA), an…
FDA Approves First Treatment for Geographic Atrophy Secondary to AMD
The FDA approved pegcetacoplan injection (Syfovre) as the first treatment for geographic…
Functional Burden Ameliorated With Newborn Screening for Spinal Muscular Atrophy
Elana Gotkine
FRIDAY, Jan. 20, 2023 (HealthDay News) -- Newborn screening for spinal muscular atrophy (SMA), together with access to disease-modifying…
Apellis Submits Marketing Authorization Application to the European Medicines Agency…
WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the…
Wasting muscles built back better: Programmable mechanically active adhesive makes…
Muscles waste as a result of not being exercised enough, as happens quickly with a broken limb that has been immobilized in a cast, and more slowly in people reaching an advanced age. Muscle…
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan…
Inclusion of the 24-month data has the potential to strengthen the product profile at launch, with minimal impact to launch timing Submission will be a Major Amendment to the New Drug…
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing…